$CELZ News

Creative Medical Technology Holdings Highlights 93% Patient Response Rate and 65% Reduction in Average Pain Scores in Ultrasome™ Knee Osteoarthritis Study

Creative Medical Technology Highlights Ultrasome Data Showing 93% Response Rate, 65% Pain Reduction In Knee Osteoarthritis Study

Creative Medical Technology Acquires 4M Additional BioDefense Stock For $200K Cash And 1M Shares, Raising Ownership To 80%

Creative Medical Technology Holdings, Inc. Expands Ultrasome™ Intellectual Property Portfolio with New U.S. Provisional Patent Filing

Creative Medical Technology Announces Filing Of New US Provisional Patent Application To Expand IP Protection Surrounding Ultrasome, Its Proprietary Cell-Free Regenerative Medicine Platform

Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning

Creative Medical Technology Stock Surges After Key Patent Win

Creative Medical Receives U.S. Patent Allowance for Exosome-Based Type 1 Diabetes Immunotherapy

Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms

Creative Medical Receives Notice Of Allowance From USPTO For US Patent Application Titled Suppression Of Diabetes Using Exosomes From Stem Cell Programmed Myeloid Cells

Creative Medical Technologies Has Received A Notice Of Allowance For A U.S. Patent Titled "SUPPRESSION OF DIABETES USING EXOSOMES FROM STEM CELL PROGRAMMED MYELOID CELLS"

Creative Medical Technology Holdings Issues Mid-Year Update

Creative Medical Technology Announces Its ADAPT Trial To Study Its CELZ-201 Is 85% Enrolled

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.5 Million Gross Proceeds

Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain

Creative Medical Technology Receives FDA Clearance To Expand Its ADAPT Clinical Trial Evaluating CELZ-201 For Chronic Lower Back Pain Associated With Degenerative Disc Disease

Creative Medical Technology opens nationwide burn-pit data registry

Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards

Creative Medical Tech Q1 EPS $(0.38) Beats $(0.39) Estimate

Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies